by Raynovich Rod | Sep 21, 2020 | Biopharmaceuticals
Update-3…2:20p Coronavirus Stocks on the Move-Rally Time for Traders In typical fashion in a momentum market when NASDAQ rallies biotech moves up.Big movers today (see chart below) are: pure play vaccine stocks BNTX, INO, MRNA, NVAX and Dx is strong as well...
by Raynovich Rod | Sep 13, 2020 | Biopharmaceuticals
Update-3 Coronavirus stocks are back led by testing boom and near term clinical news on CPOVID vaccine. Keep in mind it was a “triple witching” day.Here is a look-back to where we were with Coronavirus stocks on June 28. All pure play testing stocks are up...
by Raynovich Rod | Sep 7, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 Choppy Day but Investors coming Back to Healthcare and Biopharma. IBB and XLV up a tad. XBI flat. Rotation out of high flying tech into healthcare and industrials. Large caps winners : AMGN and GILD then AZN,RHHBY,MRK looking for large caps that have Dx and...
by Raynovich Rod | Aug 18, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
We took profits on many longs and shorts in the coronavirus sector so I will need to look at new trades for Q4. Our small longs for now are ABT, AZT, GNMK, GILD, MRNA, MRK, OSUR and TDOC. However We are also long many large caps in addition to above: ABBV, BMY, JNJ,...
by Raynovich Rod | Jun 23, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3…June 25-Re-opening Paused in FLA and TX-but stocks rally anyway. NASDAQ leads up 11% YTD. Trading remains volatile e.g. VIR. Bullish trend intact for biotech IBB up 1.11%. Vaccine stocks continue strong: BNTX INO NVAX ; MRNA lagging. Diagnostic leaders...
by Raynovich Rod | May 25, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Momentum Continues 5/29…We will update the coronavirus trade tomorrow so sign up! Today the market recovered (NAZ up 1.4%) after Trump’s rant against China. With no new news like tariffs it’s back to “don’t fight the tape, don’t...
by Raynovich Rod | Mar 2, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 nice broad biotech rally on stimulus hopes with biotech now seen as possible solution https://www.barrons.com/articles/the-dow-is-up-900-points-after-congress-agrees-on-8-3-billion-package-to-battle-coronavirus-51583350527?mod=hp_LATEST XBI up over 3%to $93...
by Raynovich Rod | Feb 11, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceutical Companies – Q1 2020 Update The IBB is at $122.69 near the 52 week high but short of 5 year high of $132.53 from Jy ’15. FWD PEs of sector are still lower than the market with S&P-500 at 18.9x. Good growth expected. Our Top...
by Raynovich Rod | Feb 6, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 2/10…Rally has expanded to mid-caps:ALNY ACAD GWPH ICPT SRPT Etc. ======= Update-1 2/7. 2p …Abbvie (ABBV) Another one of our top large cap picks ABBV is up 6% o the $92 handle as of mid-day trading on earnings and Allergan acquisition. Full year...
by Raynovich Rod | Jan 21, 2020 | Biopharmaceuticals
Update-1 We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle. Markets are jittery despite rush to new highs at opening, S&P 500 down 0.82%, as of mid-day trading over...